Cancer #ImmunogeneTherapy: Antisense and Triple Helix Aproach by Jerzy Trojan in BJSTR

Abstract

#Cellularimmunogene therapy inducing immune anti-tumor response constitutes one of the latest strategies for the treatment of many forms of cancers. From 2015, the cancer #immunotherapy became an obligatory complement therapy in USA: The Cancer Moonshot Task program supervised by USA government and the cancer immunotherapy program established in Parker Institute in Los Angeles-the common program of the best university hospitals in USA [1]. The beginning of our Anti-gene (antisense and #triplehelix) IGF-I cellular #immunogene Phase I trial in USA and Europe has presented promising results: an increase in immune response goes together with life span, and confirms the role of the immune phenomenon in the suppressing of animal tumors treated experimentally by the same cellular immunogene therapy. We need to underline, that our clinical trial was realized following the establishment of immunogene therapy as a clinical domain. This approach is based on suppression of growth factor IGF-I in #cancerscells [2-5].

For more Biomedical open access journals please click on https://biomedres.us/

For more Biomedical Research and Review articles on BJSTR

https://biomedres.us/abstracts/BJSTR.MS.ID.000919.php 

https://biomedres.us/fulltexts/BJSTR.MS.ID.000919.php 

Cancer Immunogene Therapy: Antisense and Triple Helix Aproach by Jerzy Trojan in BJSTR